JP2022535920A5 - - Google Patents

Info

Publication number
JP2022535920A5
JP2022535920A5 JP2021572548A JP2021572548A JP2022535920A5 JP 2022535920 A5 JP2022535920 A5 JP 2022535920A5 JP 2021572548 A JP2021572548 A JP 2021572548A JP 2021572548 A JP2021572548 A JP 2021572548A JP 2022535920 A5 JP2022535920 A5 JP 2022535920A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
suramin
less
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535920A (ja
JP7749169B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031217 external-priority patent/WO2020247127A1/en
Publication of JP2022535920A publication Critical patent/JP2022535920A/ja
Publication of JP2022535920A5 publication Critical patent/JP2022535920A5/ja
Application granted granted Critical
Publication of JP7749169B2 publication Critical patent/JP7749169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572548A 2019-06-07 2020-05-02 中枢神経系障害を処置するための組成物および方法 Active JP7749169B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858621P 2019-06-07 2019-06-07
US62/858,621 2019-06-07
PCT/US2020/031217 WO2020247127A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Publications (3)

Publication Number Publication Date
JP2022535920A JP2022535920A (ja) 2022-08-10
JP2022535920A5 true JP2022535920A5 (cg-RX-API-DMAC7.html) 2023-05-23
JP7749169B2 JP7749169B2 (ja) 2025-10-06

Family

ID=73652889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572548A Active JP7749169B2 (ja) 2019-06-07 2020-05-02 中枢神経系障害を処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20220226268A1 (cg-RX-API-DMAC7.html)
EP (1) EP3979985A4 (cg-RX-API-DMAC7.html)
JP (1) JP7749169B2 (cg-RX-API-DMAC7.html)
CN (1) CN114340597B (cg-RX-API-DMAC7.html)
AU (1) AU2020288999A1 (cg-RX-API-DMAC7.html)
CA (1) CA3142842A1 (cg-RX-API-DMAC7.html)
IL (1) IL288655A (cg-RX-API-DMAC7.html)
WO (1) WO2020247127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021319064A1 (en) * 2020-07-29 2023-03-23 Perfect Daylight Limited Methods of manufacture of suramin
US20230390223A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Administration of antipurinergic compositions for treating nervous system disorders
EP4229035A4 (en) * 2020-10-22 2024-07-31 Paxmedica, Inc. INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES
JP2024532288A (ja) * 2021-08-23 2024-09-05 パックスメディカ, インコーポレイテッド 抗プリン作動薬を用いて神経系障害を処置するための方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
JP2003506458A (ja) * 1999-08-11 2003-02-18 ジョセフ ピサ, シクロデキストリン誘導体の包接複合体形成の増強
JP2005519075A (ja) * 2002-02-25 2005-06-30 リフジャスロウン エイチエフ 吸収促進剤
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
FR2912591B1 (fr) * 2007-02-12 2009-05-01 Oberthur Card Syst Sa Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
US20120070487A1 (en) * 2010-03-24 2012-03-22 Aegis Therapeutics Llc Alkylsaccharide compositions with nutraceuticals
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
FR3025110B1 (fr) * 2014-09-02 2016-12-23 Univ Francois-Rabelais De Tours Dispositif de pulverisation nasale de produit fluide
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
HRP20250215T1 (hr) * 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
WO2018148580A1 (en) * 2017-02-09 2018-08-16 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Similar Documents

Publication Publication Date Title
AU2018204865B2 (en) Anticonvulsant activity of steroids
AU2023248120A1 (en) Neuroactive steroids, compositions, and uses thereof
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
AU2017379247A1 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
CN102159244A (zh) 包含减充血剂和皮质类固醇的鼻内组合物
JP2020502215A (ja) Task−1およびtask−3チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
JP2023546923A5 (cg-RX-API-DMAC7.html)
MX2010014223A (es) Composiciones pediatricas para el tratamiento de esclerosis multiple.
KR20240069750A (ko) 신경 장애의 치료
CA3124202A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
CN114903840A (zh) 一种治疗抑郁症的低剂量r-氯胺酮经鼻药物
US10966988B2 (en) Method for smoking cessation
WO2025196662A1 (en) Compositions and methods for treating eating disorders
KR20230031214A (ko) 적응 장애의 치료
JP2025160345A (ja) 薬学的組成物
EP3338764A1 (de) Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
WO2025022362A1 (en) Compositions and methods for treating dyskinesia
TW201717936A (zh) 噴霧器用組成物
EP4329722A1 (en) Use of perillyl alcohol to enhance levo-dopa delivery
HK40091740A (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
HK40020052A (en) Negundo chastetree oil solution preparation for inhalation and preparation method thereof
HK1260775B (en) Methods of increasing tonic inhibition and treating angelman syndrome